The Phase 3b COSMOS trial (ClinicalTrials.gov Identifier: NCT03796858) investigated guselkumab in patients with psoriatic arthritis that had an inadequate response to anti-tumor necrosis factor alpha (Anti-TNF Alpha) therapy. We were delighted to speak to Professor Laure Gossec (Pitie-Salpetriere Hospital and Sorbonne Universite, Paris, France) to discuss the findings from her analysis of the phase 3b COSMOS trial, which assessed the efficacy of guselkumab using multi-domain composite indices.
The abstract ‘Guselkumab efficacy in psoriatic arthritis assessed by multi-domain composite indices: data from the Phase 3b COSMOS trial in a TNFi-IR population.’ (Abstract number: POS1038) was presented at the European Congress of Rheumatology 2022, 1-4 June, 2022.
Questions
- What did the COSMOS study teach us about the efficacy and safety of guselkumab in patients with psoriatic arthritis who had inadequate response to tumour necrosis factor inhibitors? (0:23)
- Could you give us a brief overview of the aims and methodology of the current analysis? (1:54)
- What were the findings of the analysis and how clinically meaningful were these findings? (3:47)
- In an expanding treatment paradigm for psoriatic arthritis, what do you consider the place of guselkumab? (6:03)
Disclosures: Laure Gossec discloses consulting for AbbVie, Amgen, BMS, Celltrion, Galapagos, Gilead, GSK, Janssen, Lilly, MSD, Novartis, Pfizer, Sandoz and UCB; serving on advisory boards for Janssen; receiving honoraria from Janssen; and receiving research grants from Amgen, Galapagos, Lilly, Pfizer, Sandoz and UCB.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the EULAR meeting 2022.
